APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Direct Factor Xa Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Direct Factor Xa Inhibitor Market Analysis and Forecast 2026-2032

Report ID 174207460215 April 2026207 pages

Choose your research edition.

Industry ResearchOral Direct Factor Xa Inhibitor Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Direct Factor Xa Inhibitor Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Oral Direct Factor Xa Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Direct Factor Xa Inhibitor Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Oral Direct Factor Xa Inhibitor Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Oral Direct Factor Xa Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oral Direct Factor Xa Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Direct Factor Xa Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Direct Factor Xa Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Direct Factor Xa Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oral Direct Factor Xa Inhibitor include Bristol-Meyers Squibb Co, Pfizer, Boehringer Ingelheim Pharmaceuticals, Janssen Pharmaceuticals, Bayer AG, Teva Pharmaceutical Industries, Pab Organics Private Limited and Daiichi Sankyo Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oral Direct Factor Xa Inhibitor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Direct Factor Xa Inhibitor, also provides the revenue of main regions and countries. Of the upcoming market potential for Oral Direct Factor Xa Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Direct Factor Xa Inhibitor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Direct Factor Xa Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oral Direct Factor Xa Inhibitor revenue, projected growth trends, production technology, application and end-user industry.

Oral Direct Factor Xa Inhibitor Segment by Company

Bristol-Meyers Squibb Co

Pfizer

Boehringer Ingelheim Pharmaceuticals

Janssen Pharmaceuticals

Bayer AG

Teva Pharmaceutical Industries

Pab Organics Private Limited

Daiichi Sankyo Company

Oral Direct Factor Xa Inhibitor Segment by Type

Apixaban

Dabigatran

Rivaroxaban

Edoxaban

Oral Direct Factor Xa Inhibitor Segment by Application

Hospitals

Clinics

Pharmacy

Oral Direct Factor Xa Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Direct Factor Xa Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Direct Factor Xa Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Direct Factor Xa Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oral Direct Factor Xa Inhibitor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oral Direct Factor Xa Inhibitor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Direct Factor Xa Inhibitor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Direct Factor Xa Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Apixaban Major Player Table 3. Dabigatran Major Player Table 4. Rivaroxaban Major Player Table 5. Edoxaban Major Player Table 6. Global Oral Direct Factor Xa Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Player Table 8. Clinics Major Player Table 9. Pharmacy Major Player Table 10. Oral Direct Factor Xa Inhibitor Industry Trends Table 11. Oral Direct Factor Xa Inhibitor Industry Drivers Table 12. Oral Direct Factor Xa Inhibitor Industry Opportunities and Challenges Table 13. Oral Direct Factor Xa Inhibitor Industry Restraints Table 14. Global Oral Direct Factor Xa Inhibitor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oral Direct Factor Xa Inhibitor Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oral Direct Factor Xa Inhibitor Market Share by Region (2021-2026) Table 17. Global Oral Direct Factor Xa Inhibitor Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oral Direct Factor Xa Inhibitor Market Share by Region (2027-2032) Table 19. Global Oral Direct Factor Xa Inhibitor Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Players (2021-2026) Table 21. Global Oral Direct Factor Xa Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oral Direct Factor Xa Inhibitor Key Players Headquarters & Area Served Table 23. Global Oral Direct Factor Xa Inhibitor Players, Product Type & Application Table 24. Global Oral Direct Factor Xa Inhibitor Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oral Direct Factor Xa Inhibitor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oral Direct Factor Xa Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Type (2021-2026) Table 31. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Type (2027-2032) Table 32. Global Oral Direct Factor Xa Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Application (2021-2026) Table 36. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Application (2027-2032) Table 37. Bristol-Meyers Squibb Co Company Information Table 38. Bristol-Meyers Squibb Co Business Overview Table 39. Bristol-Meyers Squibb Co Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Bristol-Meyers Squibb Co Oral Direct Factor Xa Inhibitor Product Portfolio Table 41. Bristol-Meyers Squibb Co Recent Development Table 42. Pfizer Company Information Table 43. Pfizer Business Overview Table 44. Pfizer Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Pfizer Oral Direct Factor Xa Inhibitor Product Portfolio Table 46. Pfizer Recent Development Table 47. Boehringer Ingelheim Pharmaceuticals Company Information Table 48. Boehringer Ingelheim Pharmaceuticals Business Overview Table 49. Boehringer Ingelheim Pharmaceuticals Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Boehringer Ingelheim Pharmaceuticals Oral Direct Factor Xa Inhibitor Product Portfolio Table 51. Boehringer Ingelheim Pharmaceuticals Recent Development Table 52. Janssen Pharmaceuticals Company Information Table 53. Janssen Pharmaceuticals Business Overview Table 54. Janssen Pharmaceuticals Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Janssen Pharmaceuticals Oral Direct Factor Xa Inhibitor Product Portfolio Table 56. Janssen Pharmaceuticals Recent Development Table 57. Bayer AG Company Information Table 58. Bayer AG Business Overview Table 59. Bayer AG Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bayer AG Oral Direct Factor Xa Inhibitor Product Portfolio Table 61. Bayer AG Recent Development Table 62. Teva Pharmaceutical Industries Company Information Table 63. Teva Pharmaceutical Industries Business Overview Table 64. Teva Pharmaceutical Industries Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Teva Pharmaceutical Industries Oral Direct Factor Xa Inhibitor Product Portfolio Table 66. Teva Pharmaceutical Industries Recent Development Table 67. Pab Organics Private Limited Company Information Table 68. Pab Organics Private Limited Business Overview Table 69. Pab Organics Private Limited Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Pab Organics Private Limited Oral Direct Factor Xa Inhibitor Product Portfolio Table 71. Pab Organics Private Limited Recent Development Table 72. Daiichi Sankyo Company Company Information Table 73. Daiichi Sankyo Company Business Overview Table 74. Daiichi Sankyo Company Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Daiichi Sankyo Company Oral Direct Factor Xa Inhibitor Product Portfolio Table 76. Daiichi Sankyo Company Recent Development Table 77. North America Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Oral Direct Factor Xa Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Oral Direct Factor Xa Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 91. China Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 92. China Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 93. China Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 94. China Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Oral Direct Factor Xa Inhibitor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Oral Direct Factor Xa Inhibitor Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Oral Direct Factor Xa Inhibitor Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Oral Direct Factor Xa Inhibitor Image Figure 2. Global Oral Direct Factor Xa Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Direct Factor Xa Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Apixaban Image Figure 5. Dabigatran Image Figure 6. Rivaroxaban Image Figure 7. Edoxaban Image Figure 8. Global Oral Direct Factor Xa Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Oral Direct Factor Xa Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Pharmacy Image Figure 13. Global Oral Direct Factor Xa Inhibitor Market Size (US$ Million) & (2021-2032) Figure 14. Global Oral Direct Factor Xa Inhibitor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oral Direct Factor Xa Inhibitor Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oral Direct Factor Xa Inhibitor Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oral Direct Factor Xa Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oral Direct Factor Xa Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Type (2021-2032) Figure 21. Global Oral Direct Factor Xa Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Application (2021-2032) Figure 24. North America Oral Direct Factor Xa Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032) Figure 26. North America Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032) Figure 27. North America Oral Direct Factor Xa Inhibitor Revenue Share by Country (2021-2032) Figure 28. United States Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oral Direct Factor Xa Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032) Figure 33. Europe Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032) Figure 34. Europe Oral Direct Factor Xa Inhibitor Revenue Share by Country (2021-2032) Figure 35. Germany Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oral Direct Factor Xa Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032) Figure 45. China Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032) Figure 46. Asia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032) Figure 48. Asia Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032) Figure 49. Asia Oral Direct Factor Xa Inhibitor Revenue Share by Region (2021-2032) Figure 50. Japan Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oral Direct Factor Xa Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032) Figure 58. SAMEA Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032) Figure 59. SAMEA Oral Direct Factor Xa Inhibitor Revenue Share by Country (2021-2032) Figure 60. Brazil Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oral Direct Factor Xa Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Apixaban
  • Dabigatran
  • Rivaroxaban
  • Edoxaban
Applications
  • Hospitals
  • Clinics
  • Pharmacy
Companies covered
  • Bristol-Meyers Squibb Co
  • Pfizer
  • Boehringer Ingelheim Pharmaceuticals
  • Janssen Pharmaceuticals
  • Bayer AG
  • Teva Pharmaceutical Industries
  • Pab Organics Private Limited
  • Daiichi Sankyo Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Direct Factor Xa Inhibitor Market by Type
  3. 1.2.1 Global Oral Direct Factor Xa Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Apixaban
  5. 1.2.3 Dabigatran
  6. 1.2.4 Rivaroxaban
  7. 1.2.5 Edoxaban
  8. 1.3 Oral Direct Factor Xa Inhibitor Market by Application
  9. 1.3.1 Global Oral Direct Factor Xa Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Clinics
  12. 1.3.4 Pharmacy
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oral Direct Factor Xa Inhibitor Market Dynamics
  1. 2.1 Oral Direct Factor Xa Inhibitor Industry Trends
  2. 2.2 Oral Direct Factor Xa Inhibitor Industry Drivers
  3. 2.3 Oral Direct Factor Xa Inhibitor Industry Opportunities and Challenges
  4. 2.4 Oral Direct Factor Xa Inhibitor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oral Direct Factor Xa Inhibitor Market Perspective (2021-2032)
  2. 3.2 Global Oral Direct Factor Xa Inhibitor Growth Trends by Region
  3. 3.2.1 Global Oral Direct Factor Xa Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Direct Factor Xa Inhibitor Market Size by Region (2021-2026)
  5. 3.2.3 Global Oral Direct Factor Xa Inhibitor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oral Direct Factor Xa Inhibitor Revenue by Players
  2. 4.1.1 Global Oral Direct Factor Xa Inhibitor Revenue by Players (2021-2026)
  3. 4.1.2 Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oral Direct Factor Xa Inhibitor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Direct Factor Xa Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oral Direct Factor Xa Inhibitor Key Players Headquarters & Area Served
  7. 4.4 Global Oral Direct Factor Xa Inhibitor Players, Product Type & Application
  8. 4.5 Global Oral Direct Factor Xa Inhibitor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oral Direct Factor Xa Inhibitor Market CR5 and HHI
  11. 4.6.3 2025 Oral Direct Factor Xa Inhibitor Tier 1, Tier 2, and Tier 3
5 Oral Direct Factor Xa Inhibitor Market Size by Type
  1. 5.1 Global Oral Direct Factor Xa Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 5.3 Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Type (2021-2032)
6 Oral Direct Factor Xa Inhibitor Market Size by Application
  1. 6.1 Global Oral Direct Factor Xa Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  3. 6.3 Global Oral Direct Factor Xa Inhibitor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Meyers Squibb Co
  2. 7.1.1 Bristol-Meyers Squibb Co Company Information
  3. 7.1.2 Bristol-Meyers Squibb Co Business Overview
  4. 7.1.3 Bristol-Meyers Squibb Co Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Meyers Squibb Co Oral Direct Factor Xa Inhibitor Product Portfolio
  6. 7.1.5 Bristol-Meyers Squibb Co Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Oral Direct Factor Xa Inhibitor Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Boehringer Ingelheim Pharmaceuticals
  14. 7.3.1 Boehringer Ingelheim Pharmaceuticals Company Information
  15. 7.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  16. 7.3.3 Boehringer Ingelheim Pharmaceuticals Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Pharmaceuticals Oral Direct Factor Xa Inhibitor Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  19. 7.4 Janssen Pharmaceuticals
  20. 7.4.1 Janssen Pharmaceuticals Company Information
  21. 7.4.2 Janssen Pharmaceuticals Business Overview
  22. 7.4.3 Janssen Pharmaceuticals Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Janssen Pharmaceuticals Oral Direct Factor Xa Inhibitor Product Portfolio
  24. 7.4.5 Janssen Pharmaceuticals Recent Developments
  25. 7.5 Bayer AG
  26. 7.5.1 Bayer AG Company Information
  27. 7.5.2 Bayer AG Business Overview
  28. 7.5.3 Bayer AG Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer AG Oral Direct Factor Xa Inhibitor Product Portfolio
  30. 7.5.5 Bayer AG Recent Developments
  31. 7.6 Teva Pharmaceutical Industries
  32. 7.6.1 Teva Pharmaceutical Industries Company Information
  33. 7.6.2 Teva Pharmaceutical Industries Business Overview
  34. 7.6.3 Teva Pharmaceutical Industries Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Teva Pharmaceutical Industries Oral Direct Factor Xa Inhibitor Product Portfolio
  36. 7.6.5 Teva Pharmaceutical Industries Recent Developments
  37. 7.7 Pab Organics Private Limited
  38. 7.7.1 Pab Organics Private Limited Company Information
  39. 7.7.2 Pab Organics Private Limited Business Overview
  40. 7.7.3 Pab Organics Private Limited Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pab Organics Private Limited Oral Direct Factor Xa Inhibitor Product Portfolio
  42. 7.7.5 Pab Organics Private Limited Recent Developments
  43. 7.8 Daiichi Sankyo Company
  44. 7.8.1 Daiichi Sankyo Company Company Information
  45. 7.8.2 Daiichi Sankyo Company Business Overview
  46. 7.8.3 Daiichi Sankyo Company Oral Direct Factor Xa Inhibitor Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Company Oral Direct Factor Xa Inhibitor Product Portfolio
  48. 7.8.5 Daiichi Sankyo Company Recent Developments
8 North America
  1. 8.1 North America Oral Direct Factor Xa Inhibitor Revenue (2021-2032)
  2. 8.2 North America Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 8.2.1 North America Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026)
  4. 8.2.2 North America Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032)
  5. 8.3 North America Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032)
  6. 8.4 North America Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  7. 8.4.1 North America Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026)
  8. 8.4.2 North America Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032)
  9. 8.5 North America Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032)
  10. 8.6 North America Oral Direct Factor Xa Inhibitor Revenue by Country
  11. 8.6.1 North America Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026)
  13. 8.6.3 North America Oral Direct Factor Xa Inhibitor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oral Direct Factor Xa Inhibitor Revenue (2021-2032)
  2. 9.2 Europe Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032)
  5. 9.3 Europe Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032)
  9. 9.5 Europe Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oral Direct Factor Xa Inhibitor Revenue by Country
  11. 9.6.1 Europe Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oral Direct Factor Xa Inhibitor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oral Direct Factor Xa Inhibitor Revenue (2021-2032)
  2. 10.2 China Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 10.2.1 China Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026)
  4. 10.2.2 China Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032)
  5. 10.3 China Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032)
  6. 10.4 China Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  7. 10.4.1 China Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026)
  8. 10.4.2 China Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032)
  9. 10.5 China Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Direct Factor Xa Inhibitor Revenue (2021-2032)
  2. 11.2 Asia Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032)
  5. 11.3 Asia Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032)
  9. 11.5 Asia Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oral Direct Factor Xa Inhibitor Revenue by Country
  11. 11.6.1 Asia Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oral Direct Factor Xa Inhibitor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Direct Factor Xa Inhibitor Revenue (2021-2032)
  2. 12.2 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oral Direct Factor Xa Inhibitor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oral Direct Factor Xa Inhibitor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country
  11. 12.6.1 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oral Direct Factor Xa Inhibitor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst